Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

Abstract Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat biopsies (Bxs) in identifying new potential candidates with triple negative...

Full description

Saved in:
Bibliographic Details
Main Authors: Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A. Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00741-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items